MoonLake Immunotherapeutics Files 8-K on Shareholder Vote

TL;DR

MoonLake Immunotherapeutics had a shareholder vote on June 5th, filed 8-K today.

AI Summary

MoonLake Immunotherapeutics filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders on June 5, 2024. The filing details the company's principal executive offices located at Dorfstrasse 29, Zug, Switzerland.

Why It Matters

This filing indicates a formal process of shareholder decision-making, which can impact corporate governance and future strategic directions for MoonLake Immunotherapeutics.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial changes, legal issues, or operational disruptions.

Key Players & Entities

• MoonLake Immunotherapeutics (company) — Registrant
• June 5, 2024 (date) — Date of earliest event reported
• June 6, 2024 (date) — Date of report
• Dorfstrasse 29 Zug, Switzerland 6300 (location) — Principal executive offices
• Helix Acquisition Corp (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — red Class A ordinary share, par value $0.0001 per share MLTX The Nasdaq Capital M

Filing Documents

• ea0207411-8k_moonlake.htm (8-K) — 37KB
• 0001213900-24-050194.txt ( ) — 205KB
• mltx-20240605.xsd (EX-101.SCH) — 3KB
• mltx-20240605_lab.xml (EX-101.LAB) — 33KB
• mltx-20240605_pre.xml (EX-101.PRE) — 22KB
• ea0207411-8k_moonlake_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On Wednesday, June 5, 2024, MoonLake Immunotherapeutics (the "Company") held its 2024 Annual General Meeting of Shareholders (the "Annual Meeting"). As of the close of business on April 11, 2024, the record date for the Annual Meeting, there were 62,874,637 Class A Ordinary Shares and 995,267 Class C Ordinary Shares entitled to vote at the meeting. At the Annual Meeting, each of the Company's director nominees was elected, a frequency of one year received the plurality of votes cast on Proposal 4 and the other proposals voted on were approved. The final voting results are set forth below: Votes For Votes Withheld Broker Non-Votes Proposal 1. Election of Class II Director Nominees Catherine Moukheibir 50,398,781 4,335,564 4,241,512 Dr. Ramnik Xavier 53,899,047 835,298 4,241,512 Votes For Votes Against Abstentions Broker Non-Votes Proposal 2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor 52,568,361 4,220 6,403,276 0 Votes For Votes Against Abstentions Broker Non-Votes Proposal 3: Advisory Vote on Executive Compensation 54,721,123 5,234 7,988 4,241,512 1 Year 2 Years 3 Years Abstentions Broker Non-Votes Proposal 4: Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation 54,203,606 458,962 64,710 7,067 4,241,512 In light of these voting results, the Company plans to hold future advisory votes on executive compensation annually until the next required vote on the frequency of such advisory votes, or until the Board of Directors of the Company otherwise determines that a different frequency is in the best interests of the Company and its shareholders. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MoonLake Immunotherapeutics D

View Full Filing

View this 8-K filing on SEC EDGAR